BioSpace News Archive

- Patient Enrollment for GATHER2 Clinical Trial of Zimura® for the Treatment of Geographic Atrophy Secondary to Age-related Macular Degeneration Ahead of Target and Progressing Well; Completion of Enrollment Expected in 3Q of this Year - - Conference Call and Webcast Today, March 3, 2021, at 8:00 a.m. ET -

SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ™, will present a corporate overview at the upcoming virtual H.C. Wainwright Global Life Sciences Conference. The presentation will be available through the virtual conference portal on Tuesday, March 9, 2021 at 7:00 am EST.

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of Lumenis LTD

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today upcoming presentations from its HIV clinical development programs that will be featured during the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021), taking place virtually from March 6 – 10, 2021.

Transaction Furthers Kamada’s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Kamada is Already Actively Engaged in the Expansion of the Center’s Collection Capacity; Planning to Open Additional Plasma Collection Centers

Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors.

Review of TRANQUILITY data show ed 30 mcg dose met statistical significance across multiple scales Company initiated supplemental 40 mcg dose cohort to help inform clinical development strategy across the full range of dementia care settings End of Phase 2 meeting scheduled with U.S. Food and Drug Administration (“FDA”) in Q2 2021 Pivotal Phase 3 program expected to begin in the second half of 2021

Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company expects XHANCE net revenue for 2021 to be at least $80 million

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (“A.I.”) platform to improve cancer drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call

Financing led by Casdin Capital and joined by Fidelity Management & Research LLC, the Federated Hermes Kaufmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, Octagon Capital, and joined by founding investors Versant Ventures and Leaps by Bayer Capital to expand novel iPSC platform and drive product development